SLDB - Solid Biosciences Inc.
9.01 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 9.21 |
| Open | 9.21 |
| Bid | 8.90 x 3000 |
| Ask | 9.00 x 1300 |
| Day's Range | 8.93 - 9.30 |
| 52 Week Range | 5.97 - 54.84 |
| Volume | 271,681 |
| Avg. Volume | 1,069,416 |
| Market Cap | 319.16M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.25 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.83 |
- Zacks•5 days ago
Wave Life Sciences Plunges After DMD Study Data Readout
Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.
- American City Business Journals•6 days ago
Bain Capital raising another life sciences fund after $720M debut
Bain Capital is in the process of raising money for a second life sciences fund, less than two years after it amassed $720 million for its inaugural fund targeting the fast-growing sector. Bain revealed the new fund in a securities filing last week. The filing does not say how much the Boston-based private equity firm is hoping to raise.
- GlobeNewswire•7 days ago
Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., April 15, 2019 -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that preclinical data from its gene therapy program for Duchenne muscular dystrophy.
- Zacks•15 days ago
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
- American City Business Journals•25 days ago
Sarepta plans second Duchenne drug application this year
With one drug already being considered by the FDA, Sarepta Therapeutics Inc. is now planning to submit another drug for Duchenne muscular dystrophy to the FDA this year.
- GlobeNewswire•last month
Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update
CAMBRIDGE, Mass., March 13, 2019 -- Solid Biosciences Inc. (NASDAQ: SLDB) today reported financial results for the fourth quarter and fiscal year ended December 31, 2018 and.
- Investopedia•last month
10 Stocks For The Gene Therapy Revolution
Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.
- Zacks•2 months ago
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
- Zacks•2 months ago
Biotech ETFs Jump on Roche-Spark Deal
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
- Zacks•2 months ago
5 Gene Therapy Stocks to Enrich Your Portfolio
Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
- Benzinga•2 months ago
Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal
Roche Holdings AG Basel ADR (OTC: RHHBY )'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE ) has sparked a rally in the latter's shares. The Analysts ...
- PR Newswire•2 months ago
Lifshitz & Miller LLP Announces Investigation of Bristow Group Inc., Helius Medical Technologies, Inc., Nordstrom Inc., PriceSmart, Inc., Ryanair Holdings plc, Solid Biosciences Inc., and Vanda Pharmaceuticals Inc.
NEW YORK , Feb. 20, 2019 /PRNewswire/ -- Bristow Group Inc. (BRS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the Company disclosing that it "did ...
- Zacks•2 months ago
Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
- Market Realist•2 months ago
Why Solid Biosciences Stock Nosedived 67.82% Yesterday
Why Solid Biosciences Stock Nosedived 67.82% YesterdayStock price movements On February 7, Solid Biosciences (SLDB) closed at $7.19, 67.82% lower than its previous closing price, 5.27% higher than its 52-week low of $6.83, and 86.89% below its
- Motley Fool•2 months ago
What Solid Biosciences' First Failure Means for Sarepta Therapeutics
Here's why a competitor's pain was Sarepta's gain recently.
- Investor's Business Daily•2 months ago
Why This Biotech Stock Cratered 68% On Its Gene Therapy Study
Solid Biosciences crashed Thursday after its experimental gene therapy disappointed in a study of Duchenne muscular dystrophy patients. Sarepta Therapeutics, a rival, saw shares pop.
- Barrons.com•2 months ago
A Setback for Solid Is a Win for Sarepta in Race to Treat Muscular Dystrophy
Sarepta Therapeutics solidified its position as the leader in developing a gene therapy for Duchenne muscular dystrophy following disappointing data from a clinical trial released Thursday.
- Business Wire•2 months ago
SHAREHOLDER ALERT: Investigation of Solid Biosciences Inc. Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether certain statements made by Solid Biosciences, Inc. complied with federal securities laws.
- Motley Fool•2 months ago
Here's Why Solid Biosciences Plunged Today
The company announced disappointing early results for a muscular dystrophy gene therapy.
- American City Business Journals•2 months ago
Solid Biosciences shares drop 70% on disappointing Duchenne data
Cambridge biotech Solid Biosciences' stock dropped more than 70 percent Thursday after its Duchenne muscular dystrophy drug failed to come close to the effectiveness of its competitor in early tests.
- MarketWatch•2 months ago
Solid Biosciences stock falls 73% after preliminary Phase 1/2 trial shows efficacy issues with drug
Shares of Solid Biosciences fell 73% in premarket trade Tuesday after the company said preliminary findings from a Phase 1/2 clinical trial of lead candidate SGT-001 found that patients with Duchenne muscular dystrophy (DMD) who were treated with the drug showed low levels of microdystrophin protein expression. DMD is caused by mutations in the dystrophin gene -- people with the mutation can't make dystrophin protein, which is usually present in skeletal and cardiac muscles and helps protect them from injury. SGT-001 is a drug that delivers to the body a synthetic form of the dystrophin gene that codes for a replacement protein called microdystrophin. The six patients in Solid Biosciences' early-phase trial showed low levels of microdystrophin even after being treated, something the company believes can be fixed with higher doses of the drug. "We believe that SGT-001 will be a meaningful treatment for patients with DMD and are confident we have the right approach in place to evaluate its potential at higher doses. We have already begun working to expedite the planned dose escalation strategy outlined in our clinical trial protocol," said Ilan Ganot, co-founder, CEO and president of Solid Biosciences. Shares of the company have declined 17% in the year to date, while the S&P 500 has gained 9%.
- GlobeNewswire•2 months ago
Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy
Solid Biosciences (SLDB) announced today preliminary findings from IGNITE DMD, the Company’s Phase I/II dose-ascending clinical trial evaluating the safety and efficacy of SGT-001 microdystrophin gene transfer for the treatment of Duchenne muscular dystrophy (DMD). Initial three-month biopsy data showed low levels of microdystrophin protein expression. The Company is currently engaging with the appropriate parties to dose escalate as planned and as soon as possible.
- GlobeNewswire•4 months ago
Solid Biosciences to Present at the J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2019 -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot, Co-Founder, Chief Executive Officer and President of Solid Biosciences.
- GlobeNewswire•5 months ago
Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
